Abstract:BackgroundAlthough the whole tumor cell vaccine can provide the best source of immunizing antigens, there is still a limitation that most tumors are not naturally immunogenic. Tumor cells genetically modified to secrete immune activating cytokines have been proved to be more immunogenic. IL-18 could augment proliferation of T cells and cytotoxicity of NK cells. GM-CSF could stimulate dendritic cells, macrophages and enhance presentation of tumor antigens. In our study, we used mouse GM-CSF combined with IL-18 to modify Lewis lung cancer LL/2, then investigated whether vaccination could suppress tumor growth and promote survival.MethodsThe Lewis lung cancer LL/2 was transfected with co-expressing mouse GM-CSF and IL-18 plasmid by cationic liposome, then irradiated with a sublethal dose X ray (100 Gy) to prepare vaccines. Mice were subcutaneously immunized with this inactivated vaccine and then inoculated with autologous LL/2 to estimate the antitumor efficacy.ResultsThe studies reported here showed that LL/2 tumor cell vaccine modified by a co-expressing mouse GM-CSF and IL-18 plasmid could significantly inhibit tumor growth and increased survival of the mice bearing LL/2 tumor whether prophylactic or adoptive immunotherapy in vivo. A significant reduction of proliferation and increase of apoptosis were also observed in the tumor treated with vaccine of co-expressing GM-CSF and IL-18. The potent antitumor effect correlated with higher secretion levels of pro-inflammatory cytokines such as IL-18, GM-CSF, interferon-γ in serum, the proliferation of CD4+ IFN-γ+, CD8+ IFN-γ+ T lymphocytes in spleen and the infiltration of CD4+, CD8+ T in tumor. Furthermore, the mechanism of tumor-specific immune response was further proved by 51Cr cytotoxicity assay in vitro and depletion of CD4, CD8, NK immune cell subsets in vivo. The results suggested that the antitumor mechanism was mainly depended on CD4+, CD8+ T lymphocytes.ConclusionsThese results provide a new insight into therapeutic mechanisms of IL-18 plus GM-CSF modified tumor cell vaccine and provide a potential clinical cancer immunotherapeutic agent for improved antitumor immunity.

Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen

Anti-tumor Immunity with Dendritic Cells ( DC) Vaccine Modified by IL-18

Progress on Dendritic Cell Vaccines in Tumor Immunotherapy

Therapeutic Effect of MIP-1alpha-recruited Dendritic Cells on Preestablished Solid and Metastatic Tumors.

Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100

Intratumoral injection of interferon-gamma gene-modified dendritic cells elicits potent antitumor effects: effective induction of tumor-specific CD8 + CTL response

The Immunotherapeutic Effect of Dendritic Cells Vaccine Modified with Interleukin-18 Gene and Tumor Cell Lysate on Mice with Pancreatic Carcinoma

Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8 + CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells

Immunotherapy with Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrates Enhanced Antitumor Effect Against Lung Cancer

[Antitumor Immune Responses Induced by Idiotype-Pulsed Dendritic Cells with Cell-Penetrating Peptide Vaccination in Vivo].

Engineered Fusion Hybrid Vaccine of IL-18 Gene-Modified Tumor Cells and Dendritic Cells Induces Enhanced Antitumor Immunity.

Vaccination with IL-18 gene-modified, superantigen-coated tumor cells elicits potent antitumor immune response

Cancer Immunotherapy Using in Vitro Genetically Modified Targeted Dendritic Cells

Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects

Superior Anti-Tumor Protection and Therapeutic Efficacy of Vaccination with Dendritic Cell/Tumor Cell Fusion Hybrids for Murine Lewis Lung Carcinoma

Enhanced Human T Lymphocyte Antigen Priming by Cytokine-Matured Dendritic Cells Overexpressing Bcl-2 and IL-12.

Potent Antitumor Effect Elicited by Gp96-Peptide Complexes Pulsed by Dendritic Cell on Mice of H22 Liver Cancer

Neutralizing TGF-β promotes anti-tumor immunity of dendritic cells against pancreatic cancer by regulating T lymphocytes

Targeted Delivery of Tumor Antigens to Activated Dendritic Cells Via CD11c Molecules Induces Potent Antitumor Immunity in Mice

Dendritic Cell Immunotherapy Induces Anti-Tumor Effect in a Transgenic Mouse Model of Pancreatic Ductal Adenocarcinoma.

Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells.